Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84.2M
-
Number of holders
-
9
-
Total 13F shares, excl. options
-
3.95M
-
Shares change
-
+3.95M
-
Total reported value, excl. options
-
$46.1M
-
Value change
-
+$46.1M
-
Number of buys
-
9
-
Price
-
$11.66
Significant Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q2 2017
9 filings reported holding VRNA - Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share as of Q2 2017.
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) has 9 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.95M shares
of 84.2M outstanding shares and own 4.7% of the company stock.
Largest 9 shareholders include Novo Holdings A/S (741K shares), Vivo Capital, LLC (704K shares), NEA Management Company, LLC (667K shares), ORBIMED ADVISORS LLC (667K shares), Foresite Capital Management III, LLC (614K shares), Tekla Capital Management LLC (275K shares), PERCEPTIVE ADVISORS LLC (200K shares), FIL Ltd (75.8K shares), and JANE STREET GROUP, LLC (11.4K shares).
This table shows the top 9 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.